cisplatin + epirubicin + vinorelbine

The combination of cisplatin, epirubicin, and vinorelbine—often referred to as the PEV regimen—is a multi-agent chemotherapy protocol primarily investigated for use in breast cancer. Each component has a distinct mechanism of action: - Cisplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis. - Epirubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, disrupting DNA replication and repair. - Vinorelbine is a vinca alkaloid that inhibits microtubule assembly during mitosis. This combination has been studied as primary (neoadjuvant) chemotherapy for locally advanced breast cancer (T2-3 N0-2), showing high rates of tumor reduction and feasibility even in large tumors. The regimen demonstrated good tolerability with manageable hematologic toxicity and no significant cardiac toxicity reported[1][2]. It is not associated with a unique brand name but may be referenced by its acronym "PEV" in clinical literature.

Other names

PEV regimenplatinum-epirubicin-vinorelbine